Who
Robert J.R. Gunderson V
Director
Company insider
Files Form 4 as: Director, Andersen Group; Director, Theravance Biopharma; Director, Vitae Pharmaceuticals; Director, Innoviva.
In numbers
- Trades disclosed
- 48
- Buys
- 2
- Sells
- 0
- Bought
- $372K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 26 Apr 2006
- Last trade
- 20 May 2026
- Last filed
- 22 May 2026
Companies traded
Activity over time
1 Dec 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 May 2026filed 22 May 2026 | ANDG Andersen GroupBusiness Services | SEC FORM 4 Bought | $85K2,367 at $35.82 | filing |
| 20 May 2026filed 22 May 2026 | ANDG Andersen GroupBusiness Services | SEC FORM 4 Bought | $85K2,367 at $35.82 | filing |
| 18 Dec 2025filed 22 Dec 2025 | ANDG Andersen GroupBusiness Services | SEC FORM 4 Bought | $202K12,633 at $16.00 | filing |
| 27 Apr 2021filed 29 Apr 2021 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 27 Apr 2021filed 29 Apr 2021 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —9,828 at $0.00 | filing |
| 28 Apr 2020filed 30 Apr 2020 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 28 Apr 2020filed 30 Apr 2020 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —6,635 at $0.00 | filing |
| 30 Apr 2019filed 2 May 2019 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 30 Apr 2019filed 2 May 2019 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —8,385 at $0.00 | filing |
| 1 May 2018filed 3 May 2018 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —8,186 at $0.00 | filing |
| 1 May 2018filed 3 May 2018 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 17 May 2017filed 18 May 2017 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 25 Oct 2016filed 25 Oct 2016 | Vitae Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | $93K5,434 at $17.09 | filing |
| 25 Oct 2016filed 25 Oct 2016 | Vitae Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | $143K9,091 at $15.71 | filing |
| 25 Oct 2016filed 25 Oct 2016 | Vitae Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | $221K17,000 at $13.00 | filing |
| 25 Oct 2016filed 25 Oct 2016 | Vitae Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | $86K10,000 at $8.57 | filing |
| 25 Oct 2016filed 25 Oct 2016 | Vitae Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | $114K10,000 at $11.38 | filing |
| 24 Oct 2016filed 25 Oct 2016 | Vitae Pharmaceuticals | SEC FORM 4 Code U | $231K11,002 at $21.00 | filing |
| 24 Oct 2016filed 25 Oct 2016 | Vitae Pharmaceuticals | SEC FORM 4 Code U | $332K15,830 at $21.00 | filing |
| 26 May 2016filed 27 May 2016 | Vitae Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.